Abiopharma

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

UTHR: Notification

Record Trading Volume on the Nasdaq Closing Cross During the June 2026 Russell US Indexes Reconstitution

Corporación América Airports Announces Developments in the Brasilia Airport Concession Agreement

Stratus Properties Inc. Completes Sale of Jones Crossing – Retail for $46.5 Million

RTX Board of Directors Declares Quarterly Cash Dividend

Helport AI Reports First Half Fiscal Year 2026 Financial Results

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WeRide Inc. Announces Results of Annual General Meeting

FutureFuel Announces Director Resignation